Search - tctmd.com

Displaying 541 - 560 of 650

Sort: Relevancy | Date

News Daily News

Oral Anticoagulation Underused in Japanese A-fib Patients Undergoing PCI

Caitlin E. Cox

April 30, 2014

News Daily News

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

L.A. McKeown

April 11, 2014

News Conference News ACC 2014

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

Yael L. Maxwell

March 31, 2014

News Daily News

DAPT Interruption At Least 1 Month After ZES Implantation Appears Safe

Yael L. Maxwell

February 17, 2014

News Daily News

Bleeding Common but Often Unreported in ACS Patients on Antiplatelet Therapy

L.A. McKeown

February 06, 2014

News Daily News

附加西洛他唑可改善颈动脉支架植入患者的缺血性结果

January 01, 2014

News Daily News

Cilostazol Adyuvante Mejora los Resultados Isquémicos en Pacientes Implantados de Stent en la Arteria Carótida

January 01, 2014

News Daily News

Adjunctive Cilostazol Improves Ischemic Outcomes in Carotid Artery Stenting Patients

January 01, 2014

News Daily News

Un Análisis Revela que, comparados con los SMD, los SLF Reducen la RVD pero No la Mortalidad en Pacientes Muy Ancianos

December 30, 2013

News Daily News

Analysis Shows DES Reduce TVR but Not Mortality vs. BMS in Extreme Elderly

December 30, 2013

News Daily News

研究结果支持ACS患者的DAPT治疗持续3个月以上

L.A. McKeown

November 01, 2013

News Daily News

Los Hallazgos avalan una Duración de la Terapia Antiplaquetaria Doble mayor que 3 Meses en Pacientes SCA

L.A. McKeown

November 01, 2013

News Daily News

Findings Support DAPT Duration Longer Than 3 Months in ACS Patients

L.A. McKeown

November 01, 2013

News Conference News TCT 2013

OPTIMIZE: 3-Month DAPT Safe with ZES

October 31, 2013

News Industry News

New Study Finds Patients who are Event-Free Following PCI at One Year May Not Need Prolonged Dual Antiplatelet Therapy

October 31, 2013

News Industry News

New Study Demonstrates Potential Benefits of Shorter-Term Dual Antiplatelet Therapy in Patients Treated With a Second Generation Drug-Eluting Stent

October 31, 2013

News Industry News

Genetic Profiling May Provide Clinical Benefit by Identifying Heart Attack Patients That Are Resistant to Blood Thinners

October 31, 2013

News Industry News

BioFreedom™ Continues to Demonstrate Comparable Long-Term Safety and Efficacy to Conventional DES

October 31, 2013

News Conference News TCT 2013

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

October 30, 2013

News Industry News

OrbusNeich’s COMBO™ Dual Therapy Stent Shows Excellent Early Healing and Durable Outcomes out to 24 Months

October 29, 2013

Advertisement

Oral Anticoagulation Underused in Japanese A-fib Patients Undergoing PCI

Registry: DAPT Discontinuation Less Associated With Second-Gen DES Thrombosis Compared to First-Gen DES

ZES Plus Tailored Course of Dual Therapy Reduces Adverse Events in Unlikely DES Candidates

DAPT Interruption At Least 1 Month After ZES Implantation Appears Safe

Bleeding Common but Often Unreported in ACS Patients on Antiplatelet Therapy

附加西洛他唑可改善颈动脉支架植入患者的缺血性结果

Cilostazol Adyuvante Mejora los Resultados Isquémicos en Pacientes Implantados de Stent en la Arteria Carótida

Adjunctive Cilostazol Improves Ischemic Outcomes in Carotid Artery Stenting Patients

Un Análisis Revela que, comparados con los SMD, los SLF Reducen la RVD pero No la Mortalidad en Pacientes Muy Ancianos

Analysis Shows DES Reduce TVR but Not Mortality vs. BMS in Extreme Elderly

研究结果支持ACS患者的DAPT治疗持续3个月以上

Los Hallazgos avalan una Duración de la Terapia Antiplaquetaria Doble mayor que 3 Meses en Pacientes SCA

Findings Support DAPT Duration Longer Than 3 Months in ACS Patients

OPTIMIZE: 3-Month DAPT Safe with ZES

New Study Finds Patients who are Event-Free Following PCI at One Year May Not Need Prolonged Dual Antiplatelet Therapy

New Study Demonstrates Potential Benefits of Shorter-Term Dual Antiplatelet Therapy in Patients Treated With a Second Generation Drug-Eluting Stent

Genetic Profiling May Provide Clinical Benefit by Identifying Heart Attack Patients That Are Resistant to Blood Thinners

BioFreedom™ Continues to Demonstrate Comparable Long-Term Safety and Efficacy to Conventional DES

PROTECT: ZES Lowers Thrombosis Rates Over SES at 4 Years

OrbusNeich’s COMBO™ Dual Therapy Stent Shows Excellent Early Healing and Durable Outcomes out to 24 Months

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content